Entos hopes to receive emergency authorization for the vaccine by the end of the year, if it can secure the funding for future trial phases and it progresses as planned.
While most Canadians are expected to have access to vaccines by then, the global inoculation effort will be far from over. A study by a Johns Hopkins University public health researcher estimated a quarter of the global population would not have access to a COVID-19 vaccine until at least 2022. The real challenge to vaccines, as we re finding, is not whether they work or not, which luckily they do, but actually making enough of them and getting them to everybody is a monumental challenge, Lewis said.
Date Time
Made-in-Alberta COVID-19 vaccine candidate goes to clinical trials
A made-in-Alberta COVID-19 vaccine is taking a major step forward on the path to Health Canada approval with the start of a Phase 1 clinical trial.
Entos Pharmaceuticals, an Edmonton company led by CEO and University of Alberta researcher John Lewis, has shipped a vaccine for testing to the Canadian Centre for Vaccinology in Halifax. The clinical trial will test the safety of the DNA-based vaccine in 72 participants, split between young adults and older Canadians, with the aim of moving into a larger Phase 2 trial testing efficacy of the vaccine by late spring.
in the
.
Entos announces partnership with The Ottawa Hospital s Biotherapeutics Manufacturing Centre (BMC) to fill Covigenix VAX-001 in vials.
BMC and ACTM will collaborate to boost Canada s biotherapeutics manufacturing capacity.
EDMONTON, AB, Feb. 25, 2021 /CNW/ - Entos Pharmaceuticals (Entos), a biotechnology company developing genetic medicines with its Fusogenix nucleic acid delivery platform, is excited to work with Alberta Cell Therapy Manufacturing and The Ottawa Hospital s Biotherapeutics Manufacturing Centre to manufacture and ready doses of Entos made-in-Canada Covigenix VAX-001 vaccine for upcoming clinical trials at the Canadian Centre for Vaccinology.
Scientist working in the ACTM facility GMP cleanroom (CNW Group/Entos Pharmaceuticals)